WHAT IS THE EVIDENCE ON EFFECTIVENESS OF ANTIPSYCHOTICS IN PERSONS WITH DEMENTIA? 1.

Slides:



Advertisements
Similar presentations
Treating Schizophrenia in Low And Middle Income (LAMI) Countries: Challenges and opportunities Treating Schizophrenia in Low And Middle Income (LAMI) Countries:
Advertisements

New England Journal of Medicine October 18;367: Relapse Risk after Discontinuation of Risperidone in Alzheimer’s disease Molly Moncrieff.
Rethinking Behavioral Problems Associated with Dementia
The Biggest Loser Challenge: A Pill for Atypical Antipsychotic Induced-Weight Gain? Julie A. Dopheide, Pharm.D., BCPP Associate Professor of Clinical Pharmacy,
Susan Francis, PharmD, BCPS Durham VA Medical Center.
 incidence  characteristics  causes?  treatments?
Is my thyroid making me fat? Justin Moore, MD, FACP Division Chief, Endocrinology and Metabolism Medical Director, Via Christi Weight Management.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence March–April 2014.
Lucy Wang, M.D.. A 74 year old veteran with Alzheimer’s disease is referred for assistance in managing agitation. He is living in a nursing home, and.
Evidence-based Treatment of Psychotic Depression Gregory W. Dalack, MD June 22, 2006.
Efficacy and safety of angiotensin receptor blockers: a meta-analysis of randomized trials Elgendy IY et al. Am J Hypertens. 2014; doi:10,1093/ajh/hpu209.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2010.
Treatment Options for Dementia Deb Bynum, MD Division of Geriatric Medicine University of North Carolina.
Off-Label Use of Atypical Antipsychotics: An Update
1 Non-inferiority designs for relapse prevention of schizophrenia Gene Laska Ph.D. Department of Psychiatry NYU School of Medicine Nathan Kline Institute.
Rajesh R. Tampi, MD, MS, FAPA
The Clinical Antipsychotic Trials of Intervention Effectiveness Trial
Corticosteroid Randomisation After Significant Head Injury.
Antipsychotic Medications in the Primary Care Practice Angelo Potenciano, M.D.
1 Just The Facts Ma’am Dementia Care & Anti-Psychotics Just The Facts Ma’am December 17, 2012 Ronald A. Savrin, MD, MBA, FACS Medical Director, Ohio KePRO.
Best Practice Guide: Treatment and care for behavioural and psychological symptoms Clive Ballard, Anne Corbett, Alistair Burns Alzheimer’s Society UK.
Treatment for Adolescents With Depression Study (TADS)
Next-Generation Strategies for the Therapeutic Management of Schizophrenia Diana O. Perkins, MD, MPH Professor, Department of Psychiatry Medical Director.
Cardiometabolic Consequences of Risperidone in Children with Autism Cardiometabolic Consequences of Risperidone in Children with Autism Susan J. Boorin,
Medicines optimisation – a research pharmacist’s perspective Dr David Alldred Senior Lecturer in Pharmacy Practice 23 January 2015Bradford School of Pharmacy1.
RALES: Randomized Aldactone Evaluation Study Purpose To determine whether the aldosterone antagonist spironolactone reduces mortality in patients with.
CAFE TRIAL Ron Beasley, PharmD Candidate Preceptor: Soheyla Mahdavian, PharmD 1.
Lecture 9: Analysis of intervention studies Randomized trial - categorical outcome Measures of risk: –incidence rate of an adverse event (death, etc) It.
MPH Label: An opportunity Good that FDA is considering a clarification of the MPH label for safety US should invest more in safety monitoring Problems.
CC-1 Benefit-Risk Assessment Murat Emre, MD Professor of Neurology Istanbul Faculty of Medicine Department of Neurology Behavioral Neurology and Movement.
Use of Antipsychotic Drugs in Dementia Josepha A. Cheong, MD University of Florida Departments of Psychiatry and Neurology Chief, Division of Geriatric.
Schizophrenia Pathogenesis is unknown. Onset of schizophrenia is in the late teens - early ‘20s. Genetic predisposition -- Familial incidence. Multiple.
Journal of the American Medical Association (JAMA), 2004, 291:
Urine Drug Monitoring: Indiana Council of Community Mental Health Centers Jerry Vaccaro, M.D. President, Ingenuity Health October 15, 2015.
The Impact Factor (IF): What Is It Good For? Richard M. Rocco, PhD October
Prescribing in Dementia. Plan What to prescribe? When to prescribe? How to review? Who to review?
Drugs Used for Psychoses Chapter 18 Mosby items and derived items © 2010, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc.
Mental Health Nursing: Pharmacology: Antipsychotic Medications C. Calzolari 2016.
for MHD & Therapeutics is proud to present And Now Here Is The Host... Dr. Schilling.
Effects of Memantine on behavioural symptoms in Alzheimer’s disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised,
First-Generation Versus Second- Generation Antipsychotics in Adults: Comparative Effectiveness Prepared for: Agency for Healthcare Research and Quality.
Treatment for Early onset Schizophrenia Treatment for Early onset Schizophrenia Chia-Yi Christian Hospital Department of psychiatry Hou, Yuh-Ming M.D.
Pharmacogenomics: Improving the Dynamic of Care in Medication Management 1.
Elizabeth Galik, PhD, CRNP Associate Professor University of Maryland School of Nursing
Carina Signori, DO Journal Club August 2010 Macdonald, M. et al. Diabetes Care; Jun 2010; 33,
News You Can Use… Phillip Transou, PharmD Candidate Pete Koval, PharmD Cone Health Family Medicine June, 2016.
Date of download: 6/24/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Aripiprazole, an Antipsychotic With a Novel Mechanism.
SUCCESS STRATEGIES FOR REDUCING OFF-LABEL USE OF ANTIPSYCHOTIC MEDICATIONS DAVID GIFFORD, MD MPH Senior VP Quality & Regulatory Affairs RUTA KADONOFF,
Management of Geriatric Psychiatric Disorders Arash Mirabzadeh Psychiatrist University of Social Welfare and Rehabilitation Sciences.
Relapse Risk after Discontinuation of Risperidone in Alzheimer’s Disease Devanand et al NEMJ 2012; 367: By Hila Hoch, MD.
Pharmacological management of delirium
WHAT YOU NEED TO KNOW ABOUT THE USE OF ANTIPSYCHOTIC DRUGS
Nuplazid™ - Pimavanserin
Answers to Your Questions About Tardive Dyskinesia
One-Year Weight Gain While on Treatment with an Antipsychotic
Antipsychotics academic detailing
Copyright © 2005 American Medical Association. All rights reserved.
Alcohol, Other Drugs, and Health: Current Evidence
Polypharmacy and specific medication profiles as predictors of treatment and health outcomes in dementia Dr Christoph Mueller, NIHR Academic Clinical Lecturer.
Management of Agitation in Dementia
Antipsychotic Agents and Their Use in Schizophrenia
The Parkinson's Disease Psychosis Journal Club
SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.
N3-378 Template 12/31/2018 7:52 PM 8 8.
Insomnia pharmacotherapy: Off-label antipsychotics
Copyright Notice This presentation is copyrighted by the Psychopharmacology Institute. Subscribers can download it and use it for professional use. The.
Risk of perioperative renal dysfunction with N-acetylcysteine or placebo in patients undergoing CABG surgery End point N-acetylcysteine Placebo Relative.
Copyright Notice This presentation is copyrighted by the Psychopharmacology Institute. Subscribers can download it and use it for professional use. The.
Three outcome measures from the NINDS tPA trial
1 in 100 people have had a schizophrenia episode. more than 2
Presentation transcript:

WHAT IS THE EVIDENCE ON EFFECTIVENESS OF ANTIPSYCHOTICS IN PERSONS WITH DEMENTIA? 1

Atypical Antipsychotic Doses Used in Dementia MedicationLow DoseNormal Dose Aripiprazole (Abilify)<2 mg/d2-15 mg/d Olanzapine (Zyprexa)<5 mg/d5-10 mg/d Quetiapine (Seroquel)<50 mg/d mg/d Risperidone (Risperdal)<1 mg/d1-2 mg/d

Effectiveness in Dementia is weak Meta-Analysis (JAMA 2011) Zyprexa, Risperdal, and Abilify- small but statistically significant effect (12 – 20%) compared to placebo Seroquel – no statistically significant effect Antipsychotics led to an average change on the NPI of: 35% from a patient’s baseline 3.41 point difference from placebo group 30% change or 4.0 difference = minimum clinically meaningful No conclusive evidence found on comparative effectiveness of different antipsychotics Source: JAMA 306: ; Meta-analysis 38 RCTs in dementia

Net Effectiveness 4 “For every 100 patients with dementia treated with an antipsychotic medication, only 9 to 25 will benefit” Drs Avorn, Choudhry & Fishcher Harvard Medical School Dr Scheurer Medical University of South Carolina Source: Independent Drug Information Service (IDIS) Restrained Use of antipsychotic medications: rational management of irrationality. 2012

Effectiveness with Low Dose Low dose Risperdal <1 mg/d): small positive effect increased risk of adverse events Low dose Zyprexa (5 mg/d): no positive effect increased risk of adverse events Low dose Abilify and Seroquel effectiveness unknown, but Seroquel at normal dose is ineffective 5 Source: Cochrane Review 2012; Meta-analysis 16 RCTs in dementia

Adverse outcomes Off-label use of antipsychotics in nursing facility residents are associated with an increase in: Death Hospitalization Falls & fractures Venothrombolic events Conventional antipsychotics are worse than atypical antipsychotics 6

Odds of having an adverse event after receiving Risperidone 1 mg/d compared to placebo 7 Source: Cochrane Review 2012; Meta-analysis 4 RCTs in dementia Adverse EventOdds Ratio 95% Confidence Interval Mortality to 2.16 Somnolence to 3.20 Falls to 1.14 Extrapyramidal disorder to 3.17 UTI to 2.13 Edema to 5.03 Abnormal Gait to Urinary Incontinence to 101 CVA to 7.69 Drop out (had to stop meds) to 2.03

Evidence for Discontinuing Meds RCTs comparing withdrawal of medication to continuing antipsychotics will show the medication: to be effective, if more people randomized to stop the medication get worse than those randomized to continue on the medication to be ineffective, if the same percentage of people randomized to stop the medication as continue the medication get worse or do not change to be harmful, if more people randomized to stop the medication get better compared to those who continue the medication

RCT to withdraw antipsychotics w/ dementia on antipsychotics 54 continue med Outcomes assessed over 3 months Outcomes - 76% no change in behaviors - NPI total worse - Agitation worse - QOL worse - 9% stopped due to behaviors 46 stopped med Outcomes - 67% no change behaviors - NPI total worse - Agitation worse - QOL better - 13% stopped due to behaviors Meds stopped abruptly and given a placebo 2 Ballard C et al J Clin Psychiatry 2004: 65: Statistical Difference None

RCT to withdraw antipsychotics w/ dementia on antipsychotics 83 continue med Outcomes assessed after 6 months Outcomes (N=51) - Cognitive Fxn worse - NPI total worse - Verbal fluency worse - ADLs worse - Agitation 32% 82 stopped med Outcomes (N=51) - Cognitive Fxn worse - NPI total worse - Verbal Fluency better - ADLs worse - Agitation 34% Meds stopped abruptly and given a placebo 3 Ballard C et al Plos Medicine 2008; 5:e76: Statistical Difference None YES None

RCT to withdraw antipsychotics w/ Dementia with psychosis who responded to antipsychotics 32 continue med Outcomes 4 & 8 months Outcomes - 33% Relapse (n=14) - Adverse events worse - Completed trial (N=10) 40 stopped med Outcomes - 60% Relapse (n= 23) - Adverse events worse - Completed trial (n=10) Meds tapered over 1 week to placebo Statistical Difference YES None 4 Devandand DP et al NEJM 2012; 367: Third group not shown here: continued med for 4 moths then discontinued meds